Pages that link to "Q73132030"

The following pages link to Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial (Q73132030):

Displaying 21 items.

• Medical management of metastatic medullary thyroid cancer (Q27005897) (← links)
• Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry (Q27026010) (← links)
• A pretargeting system for tumor PET imaging and radioimmunotherapy (Q28087820) (← links)
• Radioimmunotherapy of human tumours (Q28088825) (← links)
• Radiation-induced tumor neoantigens: imaging and therapeutic implications (Q30473856) (← links)
• Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results (Q33409137) (← links)
• Pretargeted radioimmunotherapy for hematologic and other malignancies (Q34113941) (← links)
• Medullary thyroid cancer (Q34678745) (← links)
• Cancer Imaging and Therapy with Bispecific Antibody Pretargeting (Q36082355) (← links)
• Cancer radioimmunotherapy with alpha-emitting nuclides (Q36102652) (← links)
• Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients (Q36323585) (← links)
• Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery (Q36395999) (← links)
• Improvement of radioimmunotherapy using pretargeting (Q36941931) (← links)
• Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer. (Q37401654) (← links)
• Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody (Q40428462) (← links)
• 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland (Q42732008) (← links)
• Pretargeted radioimmunotherapy: clinically more efficient than conventional radioimmunotherapy? (Q43764750) (← links)
• Improving theranostics in pancreatic cancer (Q46466095) (← links)
• ¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. (Q53066863) (← links)
• In vivo demonstration of an active tumor pretargeting approach with peptide nucleic acid bioconjugates as complementary system. (Q55093431) (← links)
• Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC) (Q59376821) (← links)